公开(公告)号：US20220227834A1

公开(公告)日：2022-07-21

申请号：US17608546

申请日：2020-05-01

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Yong QUAN

IPC: C07K14/705 ,  A61K47/26 ,  A61K9/00 ,  A61P35/00 ,  A01K67/027

Abstract: The present disclosure provides pharmaceutical compositions comprising CD80 extracellular domain (ECD)-fragment crystallizable (Fc) fusion molecules. The present disclosure also provides methods for treating solid tumors by administering such pharmaceutical compositions.

公开(公告)号：US11306144B2

公开(公告)日：2022-04-19

申请号：US16111064

申请日：2018-08-23

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles Kaplan ,  Derrick Houser ,  Luis Borges ,  Gloria Brattich ,  David Bellovin ,  Felicia Kemp ,  Majid Ghoddusi ,  Nels P. Nielson ,  Kathy Miller ,  Maike Schmidt

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574 ,  A61K39/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

公开(公告)号：US20220073617A1

公开(公告)日：2022-03-10

申请号：US17258866

申请日：2019-07-10

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Robert J. Johnston ,  Arvind Rajpal ,  Paul O. Sheppard ,  Luis Borges ,  Andrew Rankin ,  Keith Sadoon Bahjat ,  Alan J. Korman ,  Xiaodi Deng ,  Lin Hui Su ,  Ginger Rakestraw ,  Jason R. Pinckney ,  David A. Critton ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Michael Quigley ,  Hadia Lemar ,  Akbar Nayeem

IPC: C07K16/28 ,  A61P35/00

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

公开(公告)号：US20210215687A1

公开(公告)日：2021-07-15

申请号：US17058108

申请日：2019-05-23

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Nallakkan ARVINDAN ,  Stephen MEHI ,  Guanqing OU

IPC: G01N33/543 ,  G02B21/00 ,  G02B21/16 ,  G02B13/22 ,  G02B21/26

Abstract: An optical imaging system (100) includes a frame (102) designed to provide mechanical coupling between a first stage (104) and a second stage (106), a sample holding region (108) located on the first stage (104), a lens arrangement, and a sensor array. The lens arrangement is disposed between the first stage (104) and the second stage (106) and is designed to receive light from a sample at the sample holding region (108) on the first stage. The lens arrangement has a numerical aperture less than 0.1. The sensor array is coupled to the second stage (106) and is designed to receive light passing through the lens arrangement.

公开(公告)号：US10982001B2

公开(公告)日：2021-04-20

申请号：US15152161

申请日：2016-05-11

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Justin Wong ,  Haishan Lin

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

公开(公告)号：US20210107986A1

公开(公告)日：2021-04-15

申请号：US17026853

申请日：2020-09-21

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

公开(公告)号：US20210079096A1

公开(公告)日：2021-03-18

申请号：US17006670

申请日：2020-08-28

Applicant: Five Prime Therapeutics, Inc.

Inventor： Charles KAPLAN ,  Alessandro PALUMBO ,  Kathy MILLER ,  Hangil PARK ,  Nerissa MENDOZA ,  Majid GHODDUSI

IPC: C07K16/28 ,  G01N33/574

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4 The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.

公开(公告)号：US10799559B2

公开(公告)日：2020-10-13

申请号：US16095974

申请日：2017-04-24

Applicant: Five Prime Therapeutics, Inc. ,  Glaxosmithkline Intellectual Property Development Limited

Inventor： Aaron Curtis Hinken ,  Amy W. Hsu ,  Janine Powers ,  Warren James Rocque ,  Alan James Russell

IPC: A61K38/17 ,  C07K14/705 ,  A61P7/06 ,  A61P21/00 ,  A61P25/28

Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.

公开(公告)号：US20200223931A1

公开(公告)日：2020-07-16

申请号：US16737217

申请日：2020-01-08

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K39/395 ,  A61K45/06

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

公开(公告)号：US20200031944A1

公开(公告)日：2020-01-30

申请号：US16497906

申请日：2018-03-29

Applicant: Five Prime Therapeutics, Inc.

Inventor： Susannah D. Barbee ,  David Bellovin ,  Luis Borges

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K31/7068 ,  A61K31/337 ,  A61K47/64 ,  A61K31/525 ,  A61K31/513 ,  A61K31/4745 ,  A61K31/282

Abstract: Provided herein are methods of treating cancer with a combination of an anti glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein (GITR)-antibody and an antibody that binds colony stimulating factor 1 receptor (CSF1R) or with a combination of an anti-GITR antibody and an antibody that binds programmed cell death protein 1 (PD-1).